William Feehery
Chief Executive Officer presso CERTARA, INC.
Patrimonio netto: 52 M $ in data 31/03/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Richard Traynor | M | 53 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 anni |
James Cashman | M | 70 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 anni |
Mason Slaine | M | 71 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 anni |
Stephen McLean | M | 66 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 11 anni |
Michael Schemick | M | 50 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 10 anni |
Eric Green | M | 55 | 9 anni | |
Bernard Birkett | M | 55 | 6 anni | |
Matthew Walsh | M | 57 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ.
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019. | 7 anni |
Sherilyn McCoy | F | 65 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019. | 4 anni |
Ethan Waxman | M | 35 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 4 anni |
Carol Gallagher | M | 59 |
Certara Holdings, Inc.
Certara Holdings, Inc. Packaged SoftwareTechnology Services Part of Certara, Inc., Certara Holdings, Inc. develops software for clinical pharmacology. The private company is based in Princeton, NJ. William F. Feehery has been the CEO of the company since 2019. | 2 anni |
Ellen Leinfuss | F | - |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | - |
Kimberly MacKay | F | 58 | 4 anni | |
Rosemary Crane | F | 64 | 2 anni | |
Leif Pedersen | M | 60 | 4 anni | |
Silji Abraham | M | 52 | 6 anni | |
Molly Joseph | F | 50 | 3 anni | |
Nancy Killefer | F | 69 | 3 anni | |
Deborah Keller | F | 61 | 7 anni | |
David Spaight | M | 65 | 2 anni | |
Amin Rostami-Hodjegan | M | - |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | - |
Stephen Lockhart | M | 65 | 2 anni | |
Mark Buthman | M | 63 | 13 anni | |
Cindy Reiss-Clark | F | 50 | - | |
Myla Lai-Goldman | M | 66 | 10 anni | |
Thomas Hofmann | M | 72 | 17 anni | |
Eran Broshy | M | 65 | 2 anni | |
Robert Friel | M | 68 | 4 anni | |
Paolo Pucci | M | 63 | 8 anni | |
Cynthia Collins | F | 65 | 3 anni | |
Douglas Michels | M | 66 | 13 anni | |
Elizabeth Mann | M | 48 |
Winston Churchill Foundation
| - |
Josh Xie | M | - | 3 anni | |
Robert Aspbury | M | 53 | 4 anni | |
Nicolette Sherman | F | - | 3 anni | |
Thomas Kerbusch | M | 52 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
Herbert Winokur | M | 80 |
Winston Churchill Foundation
| - |
Richard James Wilson | M | 53 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
Chad Winters | M | 45 | 5 anni | |
Annette Favorite | F | 59 | 9 anni | |
Maria Zuber | M | 66 |
Massachusetts Institute of Technology
| 29 anni |
John Gallagher | M | 51 | 1 anni | |
Nitin Patel | M | - |
Massachusetts Institute of Technology
| 29 anni |
Quintin Lai | M | 57 | 8 anni | |
Robert Segura | M | - | 3 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Donald Morel | M | 67 | 13 anni | |
Patrick Zenner | M | 77 | 20 anni | |
Michael Zhang | M | - |
Massachusetts Institute of Technology
| 11 anni |
David Vurgait | M | 59 |
University of Pennsylvania
| 1 anni |
Ioannis Kymissis | M | - |
Massachusetts Institute of Technology
| 9 anni |
Benjamin van Roy | M | - |
Massachusetts Institute of Technology
| 9 anni |
Muhammad Mohsin Al-Saggaf | M | 56 |
Massachusetts Institute of Technology
| 5 anni |
Paul Greenberg | M | - |
Massachusetts Institute of Technology
| 4 anni |
Paul Carey Konigsberg | M | - |
Massachusetts Institute of Technology
| 4 anni |
Dustin Byrne | M | - |
Massachusetts Institute of Technology
| 5 anni |
Jonathan Paul Loflin | M | - |
Massachusetts Institute of Technology
| 5 anni |
Richard J. Nelson | M | - |
Massachusetts Institute of Technology
| 5 anni |
Tom Rikert | M | - |
Massachusetts Institute of Technology
| 5 anni |
Sung-Hwan Shin | M | 61 |
Massachusetts Institute of Technology
| 7 anni |
Morten Aleksandr Engel | M | - |
Massachusetts Institute of Technology
| 5 anni |
Rob Burn | M | - |
Massachusetts Institute of Technology
| 5 anni |
Eric R. Cosman | M | - |
Massachusetts Institute of Technology
| 5 anni |
Chris Turner | M | - |
Massachusetts Institute of Technology
| 6 anni |
Vishal Kapur | M | - |
Massachusetts Institute of Technology
| 5 anni |
Errol Arkilic | M | - |
Massachusetts Institute of Technology
| 6 anni |
Alexandre Santos | M | - |
Massachusetts Institute of Technology
| 4 anni |
Michael Minnich | M | 52 |
Massachusetts Institute of Technology
| 4 anni |
David Quiram | M | 49 |
Massachusetts Institute of Technology
| 5 anni |
Sami Shalabi | M | - |
Massachusetts Institute of Technology
| 5 anni |
Ming-Hokng Maa | M | 48 |
Massachusetts Institute of Technology
| 5 anni |
Tian Hang Hu | M | 46 |
Massachusetts Institute of Technology
| 5 anni |
Jinane Abounadi | F | - |
Massachusetts Institute of Technology
| 9 anni |
Jennifer S. Moros | F | 54 |
Massachusetts Institute of Technology
University of Pennsylvania
| 7 anni |
Katie Hall | M | - |
Massachusetts Institute of Technology
| 9 anni |
Andra Bolotin | F | 61 |
Massachusetts Institute of Technology
| 2 anni |
Evren Ünver | M | - |
Massachusetts Institute of Technology
| 5 anni |
George Lloyd Miller | M | 69 | - | |
John Weiland | M | 68 | 12 anni | |
Anthony Welters | M | 69 | 19 anni | |
Yong Li | M | 55 |
University of Pennsylvania
| 4 anni |
Paritosh Somani | M | - |
Massachusetts Institute of Technology
| 4 anni |
Jake Seid | M | - |
Massachusetts Institute of Technology
| 2 anni |
Lisa Granick | F | - |
University of Pennsylvania
| 2 anni |
Ben Shih | M | - |
Massachusetts Institute of Technology
| 4 anni |
Matthias B. Jaffé | M | 50 |
Massachusetts Institute of Technology
| 3 anni |
Paula A. Johnson | M | 64 | 16 anni | |
Peter Rice | M | - |
Massachusetts Institute of Technology
| 6 anni |
Kareem Akhtar | M | - |
Massachusetts Institute of Technology
| 5 anni |
Mike Capelle | M | - |
Massachusetts Institute of Technology
| 2 anni |
Henry Chung | M | - |
Massachusetts Institute of Technology
| 5 anni |
Joan Midthun Larrea | F | 58 |
University of Pennsylvania
| 4 anni |
Eric Liu | M | 47 | 5 anni | |
Mohsin Ansari | M | - |
Massachusetts Institute of Technology
| 2 anni |
Shane M. Farritor | M | - |
Massachusetts Institute of Technology
| 5 anni |
Edmundo Manuel Muniz | M | 68 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 anni |
Yong Gang Ren | M | 59 |
Massachusetts Institute of Technology
| 5 anni |
Maria Staton | F | 54 |
Massachusetts Institute of Technology
| 2 anni |
Shiv Vikram Khemka | M | 61 |
University of Pennsylvania
| 2 anni |
John E. Paproski | M | 67 | 25 anni | |
Shalini Agarwal | F | - |
Massachusetts Institute of Technology
| 5 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 98 | 98.00% |
Regno Unito | 4 | 4.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- William Feehery
- Contatti personali